IP Library Granted Patent US 10,828,360
Granted Patent B1
US 10,828,360 · App. 16/577,955 · Granted Nov 10, 2020

Methods for inhibiting biofilm formation

Inventors: Michael Wyand (Boston, MA); John Donnelly (Boston, MA); Gerald F. Swiss (San Diego, CA)
Assignee: OneBioPharma, Inc.
A61K39/08A61K39/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,828,360
App. No.
16/577,955
Granted
Nov 10, 2020
Kind
B1
Abstract

Disclosed are methods and kits of parts useful in inhibiting biofilm formation in vivo in subjects at risk of developing biofilms. These methods include inhibiting biofilm formation where the extracellular matrix in the biofilm includes poly-β-(1→6)glucosamine structures.

Claims (16)

1. A method for inhibiting biofilm formation in such subjects which method comprises:

a) selecting an immune competent subject scheduled for implant surgery; and

b) administering to said subject prior to surgery an effective amount of a vaccine represented by formula (I):

(A-B) x —C  (I)

where A comprises from 3 to 12 repeating saccharide β-(1→6)-glucosamine units or mixtures thereof having the formula:

x represents the loading factor and is an integer from 10 to 40;

y is an integer from 1 to 10;

B is a linker group connecting A to C; and

C is an antigenic carrier; and

c) maintaining said patient under conditions where endogenous antibodies against said oligo-β-(1→6)-glucosamine units are present provided that said antibodies are generated prior to implantation surgery so as inhibit formation of biofilm formation in said subject subsequent to said surgery.

2. The method of claim 1 , wherein said vaccine is administered in a pharmaceutical composition.

3. The method of claim 2 , wherein said pharmaceutical composition comprises an aqueous diluent and an adjuvant.

4. The method of claim 3 , wherein said composition is sterile.

5. The method of claim 1 , wherein y is a single integer.

6. The method of claim 1 , wherein y is a mixture of integers.

7. The method of claim 1 , wherein the carrier is a tetanus toxoid.

Assignments (2)
CHANGE OF NAME Recorded Apr 13, 2022
From: ONEBIOPHARMA INC.
To: ALOPEXX INC.
Reel/Frame 060517/0070 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2020
From: WYAND, MICHAEL; DONNELLY, JOHN; SWISS, GERALD F.
To: ONEBIOPHARMA, INC.
Reel/Frame 053015/0812 →